Department of Thoracic Surgery, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou 310000, China.
Thoracic Oncology Department, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou 310000, China.
J Tradit Chin Med. 2024 Oct;44(5):1000-1005. doi: 10.19852/j.cnki.jtcm.20240806.008.
To assess clinical value of modified Shenling Baizhu powder (, SBP) in intervening targeted therapy-induced diarrhea.
This study was a prospective randomized controlled study. Eighty-five non-small cell lung cancer (NSCLC) patients with diarrhea who took targeted drugs were randomly divided into two groups. The experimental group received modified SBP, while the control group received imodium. During 2 courses of treatment (1 week/course) and 2 weeks of follow-up, we observed remission and recurrence of diarrhea, as well as the improvement of Karnofsky score (KPS) in the two groups and drug safety.
Eighty cases were completed, with 40 cases in the experimental group and 40 cases in the control group. The control group's diarrhea remission rate was significantly lower than the experimental group's (<0.05). After 2 courses of treatment, the symptom scores of both groups were lower than before, with that of the experimental group remarkably lower (<0.05). Furthermore, the experimental group experienced less abdominal fullness and appetite loss than the control group (<0.05). There was no prominent difference in overall diarrhea recurrence, time, or KPS after treatment between the two groups (>0.05). No unique adverse events occurred in experimental group or control group.
The modified SBP could improve targeted therapy-induced diarrhea in NSCLC, and is superior to imodium in relieving diarrhea, improving related symptom scores and symptoms, with no obvious drug-related adverse events.
评估加味参苓白术散干预靶向治疗相关性腹泻的临床价值。
前瞻性随机对照研究。将 85 例接受靶向药物治疗并发生腹泻的非小细胞肺癌患者随机分为两组，实验组服用加味参苓白术散，对照组服用易蒙停。观察两组腹泻缓解及复发情况、卡氏评分（KPS）改善情况及药物安全性，疗程为 2 周（1 周/疗程），随访 2 周。
80 例患者完成研究，实验组和对照组各 40 例。对照组腹泻缓解率明显低于实验组（P<0.05）。治疗 2 个疗程后，两组症状评分均低于治疗前，实验组显著低于对照组（P<0.05）。实验组腹胀、食欲下降发生率低于对照组（P<0.05）。两组腹泻总复发率、复发时间及治疗后 KPS 比较差异均无统计学意义（P>0.05）。两组均未出现明显药物相关不良反应。
加味参苓白术散可改善 NSCLC 患者靶向治疗相关性腹泻，在缓解腹泻、改善相关症状评分及症状方面优于易蒙停，且无明显药物相关不良反应。
